CellBioN, Quracle Spark Commercialization Hopes[K-bio Pulse]

[Kim Jiwan, Edaily Reporter] On the 29th Korea’s pharmaceutical and biotech sector is seeing simultaneous expectations for a corporate value re-rating, driven by a convergence of clinical achievements technology partnerships, and regulatory approval momentum.

Curacle states on its website that CU01 targets microvascular dysfunction.

(Source: Screenshot captured by reporter Jiwan Kim) Curacle is raising expectations for a potential technology transfer following the success of its Phase 2b clinical trial of CU01, a treatment for kidney disease, and the filing of a new use patent.